Navigation Links
AbbVie and Alvine to Collaborate on Investigational Oral Therapy for Celiac Disease
Date:5/14/2013

clinical-stage, specialty biopharmaceutical company located in San Carlos, CA, focused on the development of biologics targeting autoimmune and inflammatory diseases, including celiac disease.  Alvine is focusing clinical development efforts on ALV003, an investigational drug in Phase 2 trials that could potentially be the first approved therapeutic treatment for patients with celiac disease.  For additional information about the company, please visit http://www.alvinepharma.com.

AbbVie Forward-Looking Statements

Some statements in this news release may be forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.  The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements.  AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.  Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry.  Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," in our 2012 Annual Report on Form 10-K/A, which has been filed with the Securities and Exchange Commission.  AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

About AbbVie

AbbVie is a global, research-based biopharmaceutical company formed in 2013 follo
'/>"/>

SOURCE AbbVie
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AbbVie to Present at Bank of America Merrill Lynch 2013 Health Care Conference
2. AbbVies Investigational HCV Regimen Receives Breakthrough Therapy Designation from the U.S. Food and Drug Administration
3. AbbVie CF Scholarship Application Now Available for Exceptional Undergraduate and Graduate Students with Cystic Fibrosis
4. AbbVie Reports First-Quarter 2013 Financial Results
5. AbbVie to Host First-Quarter Earnings Conference Call
6. Receptos Licenses Anti-Interleukin-13 Antibody from AbbVie for Phase 2 Development in Orphan Disease
7. AbbVie to Present at Barclays Global Health Care Conference
8. AbbVie Issues Inaugural Full-Year Outlook for 2013
9. AbbVie Named to S&P 500 Dividend Aristocrat Index
10. Domain Associates and Elite Consulting Collaborate to Create and Invest in Life Science Companies in China
11. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/29/2015)... 2015  Eli Lilly and Company (NYSE: LLY ... that they have entered into a clinical trial collaboration ... investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with ... cancer medicine. The planned study will assess the combination ... The Phase I study is expected to ...
(Date:5/29/2015)... -- World-renowned prostate surgeon and New York Urologist, Dr. David ... MR/Ultrasound Fusion-Guided Biopsy for detecting aggressive prostate cancer ... at Lenox Hill Hospital is the only center using the ... York City . We,ve seen tremendous improvement in detecting ... of an MRI makes for a much more accurate diagnosis, ...
(Date:5/28/2015)... , May 28, 2015  Eli Lilly and Company ... its previously announced cash tender offer for up to $1.6 ... securities. Holders of notes who tendered, and did ... New York City time, on May ... for purchase by Lilly, are eligible to receive the total ...
Breaking Medicine Technology:Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 2Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 3Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 4Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 5Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 6Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 7Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 8Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 9Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 10Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 11Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 12Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 13Lilly and AstraZeneca to Collaborate on Immuno-Oncology Combination Clinical Trial in Solid Tumors 14MR/Ultrasound Fusion-Guided Biopsy Better Able to Detect Aggressive Prostate Cancer, New Study Says 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 2Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 3Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 4Lilly Announces the Pricing Terms of Its Cash Tender Offer for Up to $1.6 Billion Aggregate Principal Amount of Its Outstanding Debt Securities 5
...  Watson Pharmaceuticals, Inc. (NYSE: WPI ), a ... Olafsson, Watson,s President of Global Generics, will provide an ... Jefferies 2012 Global Healthcare Conference on Monday, June 4, ... in New York, New York.  The presentation will be ...
... May 25, 2012  Marken announced today that it has ... will manage customer service operations and offer local service ... Korea.  Marken currently operates in the country through its ... out of the country.  This new office has been ...
Cached Medicine Technology:Watson to Present at the Jefferies 2012 Global Healthcare Conference 2Marken Opens Branch Office In Seoul, South Korea 2
(Date:5/29/2015)... Displays and Exhibits’ has recently aligned with ... of hanging signs ; making what was formerly an ... from ceiling rigging points at a usual height of 16’-20’ ... These signs are very unique and more visible than ... installation and dismantle labor and rigging the costs far outweigh ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 Ready to hit ... important for all drivers to get their vehicles ready. With ... be prepared. Advanced Driving Systems (ADS) is ready to help ... on preparing for summer road trips. , When planning for ... following to ensure that the trip goes smoothly and they ...
(Date:5/29/2015)... PA (PRWEB) May 29, 2015 M3 ... quiz-based learning in 14 medical specialties, now offers ... a wide spectrum of rheumatology disorders ranging from Fibromyalgia ... Saint Jacques, editorial director of MDLinx, and Caroline Tredway, ... about the impact it will have on the physicians ...
(Date:5/29/2015)... 2015 Abington Hospital – Jefferson ... first hospitals in the nation to join the ... practices and work toward achieving the Baby-Friendly USA© ... focusing on maternity care practices leading to Baby-Friendly ... and Prevention, EMPower is aimed at increasing breastfeeding ...
(Date:5/29/2015)... Dot Hill can mark one more item off her bucket list: ... retirement community is the oldest woman to have flown at ... great fun!”, she exclaimed. “I’ve always wanted to jump from ... thought this would be ok.” , “We put on nylon coveralls, ... described. “I don’t remember it being noisy, but the wind ...
Breaking Medicine News(10 mins):Health News:Displays and Exhibits Announces New Hanging Sign Supplier 2Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 2Health News:Advanced Driving Systems Offers Tips for Summer Road Trips 3Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Abington Hospital Selected to Join Baby-Friendly Hospital Initiative 2Health News:Indoor Skydiving Brings Thrills to Seniors 2
... ... Asia Research News 2010 is now available online and in print. , ... (PRWebUK) June 24, 2010 -- We are pleased ... Asia Research News , , , , ,The magazine features interesting on-going research from ...
... Doheny HealthDay Reporter , THURSDAY, June 24 ... to reduce the risk of invasive breast cancer by ... a woman is considering bisphosphonate use for bone, this ... Chlebowski, a clinical oncologist at the Los Angeles Biomedical ...
... HealthDay Reporter , THURSDAY, June 24 (HealthDay News) -- Ninety ... a new government report reveals. In fact, salt is ... people to consume less. Too much salt can increase your ... and stroke. "Nine in 10 American adults consume more ...
... readily and safely distinguished the brains of Alzheimer,s disease ... the doors to making such imaging available beyond facilities ... reported by a Johns Hopkins team in the June ... better ways to distinguish Alzheimer,s from other types of ...
... Medical Centre in The Netherlands found that cyclosporine treatment ... de novo cancer in liver transplant patients. Full details ... , a journal published by Wiley-Blackwell on behalf of ... (AASLD). The 1-year survival rate after liver transplantation ...
... studies have shown that antiviral treatment reduces the incidence ... B (CHB). But now, researchers from the Division of ... that the antiviral therapy also prevents recurrence of HCC ... care for patients with HCC is local ablation of ...
Cached Medicine News:Health News:Asia Research News 2010 2Health News:Asia Research News 2010 3Health News:Bone-Building Pills Appear to Lower Invasive Breast Cancer Risk 2Health News:Bone-Building Pills Appear to Lower Invasive Breast Cancer Risk 3Health News:Most Americans Get Too Much Salt 2Health News:Most Americans Get Too Much Salt 3Health News:Novel radiotracer shines new light on the brains of Alzheimer's disease patients 2Health News:Higher cancer rates found in liver transplant patients receiving cyclosporine for immunosuppression 2Health News:Higher cancer rates found in liver transplant patients receiving cyclosporine for immunosuppression 3Health News:Silencing hepatitis B virus prevent recurrence of liver cancer 2
1.2% Tryptone, 2.4% Yeast Extract, 1.6% Glycerol, 100 ml of 10x Phosphate buffer supplement....
5.0% Casein digest (NZ amine), 2.5% Sodium Chloride, 2.5% Yeast Extract....
1.0% Casein digest (NZ amine), 0.5% Sodium Chloride, 0.5% Yeast Extract, 1.0% bacto casamino acids, 0.2% Mag. Sulfate....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride....
Medicine Products: